Wirth Peter
Director at SYRS; Director at ZLAB; Director at Forma Therapeutics Holdings, Inc.,, and 1 more
- Sold, on record
- $18.5M
- Dollars the filings state
- Form 4 sales
- 5
- Latest Dec 8, 2022
- Form 144 notices
- 1
- Proposed sales
- Quarters with a sale
- 0 of the last 8
- No sale in two years
- Companies
- 4
- Filed as an executive or holder
Companies
- SYRSSyros Pharmaceuticals, Inc.Director
- ZLABZai Lab LtdDirector
- Forma Therapeutics Holdings, Inc.,Director
- GENZYME CORPExec VP,Legal & Corporate Dev.
Sales by reason
0
Routine
1
Plan not stated
0
No plan
4
Unusual
Form 4 sales per year, every sale on record.
Sales by company
- GENZYME CORP287,061 shares
- Forma Therapeutics Holdings, Inc.,78,454 shares
- ZLAB7,852 shares
Shares sold, every Form 4 sale on record.
Timeline
- Mar 11, 2025Notice
Filed a notice to sell 9,333 shares
$2k9,333 shares
- Dec 8, 2022Plan not stated
Sold 2.2% of their holdings
$278k7,852 shares at $35.35
- Jun 23, 2020Unusual
Forma Therapeutics Holdings, Inc.,
Sold 100% of their holdings
78,454 shares
- May 25, 2010Unusual
Sold 30.5% of their holdings
$304k6,665 shares at $45.62
- May 17, 2010Unusual
Sold 87.6% of their holdings
$2.4M48,216 shares at $50.51
- Jan 16, 2009Unusual
Sold 97.5% of their holdings
$15.4M232,180 shares at $66.50
6 of 6
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Jun 22, 2026 | ZLAB | Director | Awarded | 22,371 | 416,121 | SEC | ||
| Jun 18, 2025 | Jun 23, 2025 | ZLAB | Director | Awarded | 10,831 | 393,750 | SEC | ||
| Jun 18, 2024 | Jun 20, 2024 | ZLAB | Director | Awarded | 21,253 | 382,919 | SEC | ||
| Jun 5, 2024 | Jun 7, 2024 | SYRS | Director | AwardedStock Option (right to buy) | 6,000 | 6,000 | SEC | ||
| Jun 5, 2024 | Jun 7, 2024 | SYRS | Director | Awarded | 4,000 | 16,000 | SEC | ||
| Jun 29, 2023 | Jun 30, 2023 | ZLAB | Director | Awarded | 18,903 | $26.45 | $500k | 361,666 | SEC |
| Jun 1, 2023 | Jun 2, 2023 | SYRS | Director | AwardedStock Option (right to buy) | 6,000 | 6,000 | SEC | ||
| Jun 1, 2023 | Jun 2, 2023 | SYRS | Director | Awarded | 4,000 | 12,000 | SEC | ||
| Dec 8, 2022 | Dec 9, 2022 | ZLAB | Director | Sold | 7,852 | $35.35 | $278k | 0 | SEC |
| Oct 14, 2022 | Oct 14, 2022 | Forma Therapeutics Holdings, Inc., | Director | Tendered | 134,915 | 0 | SEC | ||
| Oct 14, 2022 | Oct 14, 2022 | Forma Therapeutics Holdings, Inc., | Director | Returned to the companyStock Option (Right to Buy) | 74,737 | 0 | SEC | ||
| Sep 16, 2022 | Sep 19, 2022 | SYRS | Director | AwardedStock Option (right to buy) | 12,000 | 12,000 | SEC | ||
| Sep 16, 2022 | Sep 19, 2022 | SYRS | Director | Awarded | 8,000 | 8,000 | SEC | ||
| Jun 8, 2022 | Jun 9, 2022 | Forma Therapeutics Holdings, Inc., | Director | AwardedStock Option (Right to Buy) | 6,750 | 6,750 | SEC | ||
| Jun 8, 2022 | Jun 9, 2022 | Forma Therapeutics Holdings, Inc., | Director | Awarded | 4,500 | 134,915 | SEC | ||
| Jun 1, 2022 | Jun 2, 2022 | SYRS | Director | AwardedStock Option (right to buy) | 17,500 | 17,500 | SEC | ||
| Jan 3, 2022 | Jan 4, 2022 | ZLAB | Director | Awarded | 7,763 | 350,615 | SEC | ||
| Dec 8, 2021 | Dec 8, 2021 | ZLAB | Director | Bought | 4,000 | $71.36 | $285k | 342,852 | SEC |
| Jun 17, 2021 | Jun 21, 2021 | Forma Therapeutics Holdings, Inc., | Director | AwardedStock Option (Right to Buy) | 8,375 | 8,375 | SEC | ||
| Jun 17, 2021 | Jun 21, 2021 | Forma Therapeutics Holdings, Inc., | Director | Awarded | 2,750 | 130,415 | SEC | ||
| Jun 8, 2021 | Jun 10, 2021 | SYRS | Director | AwardedStock Option (right to buy) | 17,500 | 17,500 | SEC | ||
| Jan 15, 2021 | Jan 20, 2021 | ZLAB | Director | Awarded | 3,852 | 338,852 | SEC | ||
| Jun 23, 2020 | Jun 24, 2020 | Forma Therapeutics Holdings, Inc., | Director | Sold | 78,454 | 0 | SEC | ||
| Jun 23, 2020 | Jun 24, 2020 | Forma Therapeutics Holdings, Inc., | Director | Bought | 63,299 | 127,665 | SEC | ||
| Jun 18, 2020 | Jun 22, 2020 | Forma Therapeutics Holdings, Inc., | Director | AwardedStock Option (Right to Buy) | 17,533 | 0 | SEC | ||
| Jun 11, 2020 | Jun 11, 2020 | SYRS | Director | AwardedStock Option (right to buy) | 17,500 | 17,500 | SEC | ||
| Jun 11, 2019 | Jun 12, 2019 | SYRS | Director | AwardedStock Option (right to buy) | 11,000 | 11,000 | SEC | ||
| Jun 14, 2018 | Jun 15, 2018 | SYRS | Director | AwardedStock Option (right to buy) | 11,000 | 11,000 | SEC | ||
| Jan 27, 2017 | Jan 30, 2017 | SYRS | Director | AwardedStock Option (Right to Buy) | 22,000 | 22,000 | SEC | ||
| Jun 22, 2015 | Jun 23, 2015 | TRIMERIS INC | Director | Returned to the companyStock Options (Right to Buy) | 30,000 | 0 | SEC | ||
| Jun 4, 2014 | Jun 5, 2014 | TRIMERIS INC | Director | AwardedStock Option (Right to Buy) | 7,500 | 7,500 | SEC | ||
| Jun 6, 2013 | Jun 10, 2013 | TRIMERIS INC | Director | AwardedStock Option (Right to Buy) | 7,500 | 7,500 | SEC | ||
| Jun 27, 2012 | Jun 29, 2012 | TRIMERIS INC | Director | AwardedStock Option (Right to Buy) | 15,000 | 15,000 | SEC | ||
| Apr 4, 2011 | Apr 6, 2011 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Tendered | 15,808 | $74.00 | $1.2M | 0 | SEC |
| Apr 4, 2011 | Apr 6, 2011 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Exercised or settledRestricted Stock Units | 29,250 | 0 | SEC | ||
| Apr 4, 2011 | Apr 6, 2011 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Exercised options | 29,250 | 44,910 | SEC | ||
| Apr 4, 2011 | Apr 6, 2011 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Returned to the companyStock Option (right to buy) | 734,045 | $49.21 | $36.1M | 0 | SEC |
| Apr 4, 2011 | Apr 6, 2011 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Returned to the company | 29,250 | $74.00 | $2.2M | 0 | SEC |
| Jun 16, 2010 | Jun 18, 2010 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | AwardedStock Option (right to buy) | 42,750 | $51.52 | $2.2M | 42,750 | SEC |
| May 25, 2010 | May 26, 2010 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Sold | 6,665 | $45.62 | $304k | 15,191 | SEC |
| May 24, 2010 | May 26, 2010 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Exercised or settledRestricted Stock Units | 15,000 | 0 | SEC | ||
| May 24, 2010 | May 26, 2010 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Exercised options | 15,000 | 21,856 | SEC | ||
| May 17, 2010 | May 19, 2010 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Sold | 48,216 | $50.51 | $2.4M | 6,856 | SEC |
| May 17, 2010 | May 19, 2010 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Exercised or settledStock Option (right to buy) | 48,216 | $26.50 | $1.3M | 0 | SEC |
| May 17, 2010 | May 19, 2010 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Exercised options | 48,216 | $26.50 | $1.3M | 55,072 | SEC |
| May 21, 2009 | May 26, 2009 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | AwardedRestricted Stock Units | 57,000 | 42,750 | SEC | ||
| Jan 16, 2009 | Jan 20, 2009 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Sold | 232,180 | $66.50 | $15.4M | 6,068 | SEC |
| Jan 16, 2009 | Jan 20, 2009 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Exercised or settledGenzyme NQ stock option (right to buy) | 232,180 | 0 | SEC | ||
| Jan 16, 2009 | Jan 20, 2009 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Exercised options | 232,180 | $29.44 | $6.8M | 238,248 | SEC |
| May 22, 2008 | May 27, 2008 | GENZYME CORP | Executive Vice President | AwardedGenzyme NQ Stock Option (right to buy) | 60,000 | 15,000 | SEC |
Page 1
Sales and notices (6)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2025 | Mar 11, 2025 | SYRS | Director | Form 144 notice | 9,333 | $2k | Notice | SEC | |
| Dec 8, 2022 | Dec 9, 2022 | ZLAB | Director | Form 4 sale | 7,852 | $278k | 2.2% | Plan not stated | SEC |
| Jun 23, 2020 | Jun 24, 2020 | Forma Therapeutics Holdings, Inc., | Director | Form 4 sale | 78,454 | 100.0% | Unusual | SEC | |
| May 25, 2010 | May 26, 2010 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Form 4 sale | 6,665 | $304k | 30.5% | Unusual | SEC |
| May 17, 2010 | May 19, 2010 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Form 4 sale | 48,216 | $2.4M | 87.6% | Unusual | SEC |
| Jan 16, 2009 | Jan 20, 2009 | GENZYME CORP | Exec VP,Legal & Corporate Dev. | Form 4 sale | 232,180 | $15.4M | 97.5% | Unusual | SEC |